摘要
目的:探讨表皮生长因子受体(ep iderm a l grow th factor receptor,EGFR)、表皮生长因子受体Ⅲ型突变体(ep iderm a lgrow th factor receptor varian t typeⅢ,EGFR vⅢ)与肝细胞癌(HCC)的关系。方法:应用免疫组化SP方法检测55例HCC及癌旁肝组织中EGFR和EGFR vⅢ的表达情况。结果:EGFR在HCC中的阳性表达率(58.18%,32/55)高于癌旁肝组织的阳性率(36.36%,20/55),两组差异有统计学意义(P<0.05)。EGFR vⅢ在HCC中的阳性率(61.82%,34/55)高于癌旁肝组织的阳性率(38.18%,21/55),两组差异有统计学意义(P<0.05)。EGFR蛋白在HCC组织中的检出率与临床分期、门静脉癌栓、肝外转移、术后复发相关(P<0.05),EGFR vⅢ蛋白在HCC组织中的检出率与临床分期、门静脉癌栓、肝外转移、术后复发、肿瘤大小相关(P<0.05)。结论:EGFR、EGFR vⅢ在HCC的发生、发展和转移中起重要作用,可作为预测HCC复发、转移的参考指标。
Objective:To investigate the relation of the epidermal growth factor receptor (EGFR) and the epidermal growth factor receptor variant type Ⅲ (EGFRv Ⅲ ) with human HCC tissues. Methods.. Immunohistochemistry was employed to determine the expression of EGFR and EGFRv Ⅲ in 55 HCC tissues and theiradjacent liver tissues. Result:The positive rate of EGFR in the HCC tissue(58.18%, 32/55) was markedly higher than in the adjacent liver tissue (36.36%,20/55)( P 〈0.05). The positive rate of EGFRv Ⅲ was significantly higher in the HCC tissue (61. 82%,34/55) than in the adjacent liver tissue (38.18%, 21/55) (P 〈0.05). EGFR and EGFRv Ⅲ expression upregulate in HCC, The expression of EGFR in the HCC tissue was significantly correlated with the clinical stage, the portal vein tumor thrombus, the presence of extrahepatic metastasis and the recurrence of tumor. The positive rate of EGFRv Ⅲ in the HCC tissue was significantly correlated with the clinical stage, the portal vein tumor thrombus, the presence of extrahepatic metastasis, the recurrence of tumor and the diameter of tumor. Conclusion:EGFR and EGFRv Ⅲ expression upregulation in HCC,indicates the importance of EGFR and EGFRv Ⅲ in the pathogenesis and progression of HCC,and they can be used as a valuable marker for predicting the metastasis and recurrence of HCC.
出处
《广西医科大学学报》
CAS
北大核心
2005年第6期853-855,共3页
Journal of Guangxi Medical University
基金
广西留学回国人员科学基金资助项目(No.桂科回0009012)
关键词
表皮生长因子受体
表皮生长因子受体Ⅲ型突变体
肝细胞癌
epidermal growth factor receptor
epidermal growth factor receptor variant type Ⅲ
hepatocellular carcinoma